title: [Disease modifying drugs in multiple sclerosis and pregnancy].
authors: Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat), Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital Vall d'Hebron, Barcelona, España. ctur@cem-cat.org
authors: Carmen
authors: C
authors: Tur
authors: Mar
authors: M
authors: Tintoré
authors: Cristina
authors: C
authors: Aguilera
mesh_terms: D000014:Abnormalities, Drug-Induced; D000022:Abortion, Spontaneous / Q000139:chemically induced; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D000068876:Fingolimod Hydrochloride; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007231:Infant, Newborn; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D050497:Stillbirth
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D010455:Peptides; D011409:Propylene Glycols; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine